Our study identified Slc22a17 as a potential drug target to design therapies for interventions to enhance neurogenesis in Alzheimer’s disease and proposed additional candidate genes potentially functioning in the NGFR/p75NTR pathway. The gene discussed is NGFR; the disease is early-onset autosomal dominant Alzheimer disease.